抗性结肠炎效果和乙烯酸乙烯提取物中的活性成分来自Sargentodoxa cuneata的
Piao Yu1, Feng Xu1, Hongmei Wu1
1Department of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Molecules (Basel, Switzerland)
|November 25, 2023
概括
来自Sargentodoxa cuneata (EAdSc) 的乙酸提取物在治疗性结肠炎 (UC) 中显示出有前途. 研究表明,EAdSc通过向关键炎症路径来减少炎症和结肠损伤,为这种慢性疾病提供了潜在的新疗法.
科学领域:
- 药理学和传统医学的医学.
- 胃肠病学和炎症性疾病
背景情况:
- 性结肠炎 (UC) 是一种衰弱的慢性炎症性肠病,治疗选择有限.
- 从Sargentodoxa cuneata (EAdSc) 中提取的乙烯提取物表现出潜在的抗炎性质,但其在UC中的有效性尚未研究.
研究的目的:
- 在性结肠炎 (UC) 的小鼠模型中探索EAdSc的治疗潜力和潜在机制.
- 确定EAdSc的活性化合物和关键分子标,用于治疗UC.
主要方法:
- 使用GC-MS和LC-MS对EAdSc进行化学分析,以识别成分化合物.
- 网络药理学和分子对接分析,以预测治疗点和活性成分.
- 评估EAdSc在硫酸 (DSS) 诱导的UC小鼠模型中的疗效,评估疾病活性,结肠损伤和炎症标志物.
主要成果:
- EAdSc治疗显著改善了DSS诱导的UC,减少了疾病活性,结肠缩短和组织学损伤.
- 网络药理学和分子对接确定了关键化合物 (例如,eleutheroside A, liriodendrin) 和TLR4/NF-κB/NLRP3通路作为关键目标.
- EAdSc的使用降低了促炎性细胞因子 (TNF-α,IL-1β,IL-6,IL-17) 的含量,并抑制了结肠组织中TLR4,NF-κB p65,NLRP3和Caspase-1的表达.
结论:
- EAdSc在小鼠的实验性性结肠炎中显示出显著的治疗效果.
- EAdSc的抗UC机制涉及TLR4/NF-κB/NLRP3炎症通路的调节和关键细胞因子的减少.
- EAdSc为性结肠炎提供了一个有前途的天然治疗剂,其特定的化合物被确定为潜在的活性成分.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Drugs for Treatment of Constipation-Predominant IBS
179
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
179
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
449
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
449
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
214
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
214


